Literature DB >> 29924963

Do hepatocellular carcinomas located in subcapsular space or in proximity to vessels increase the rate of local tumor progression? A meta-analysis.

Zhi-Cheng Lai1, Jin-Yu Liang2, Li-Da Chen3, Zhu Wang4, Si-Min Ruan5, Xiao-Yan Xie2, Ming-De Lu6, Hang-Tong Hu7, Wei Wang8.   

Abstract

AIMS: To determine if tumors located in the subcapsular space or in proximity to vessels would be a risk factor of local tumor progression (LTP2) in hepatocellular carcinomas (HCC) after radiofrequency ablation.
MATERIALS AND METHODS: A search of the MEDLINE, EMBASE and Cochrane Library databases from 1998 to 2017 was performed to identify studies examining the risk factors of LTP after radiofrequency ablation (RFA3) in HCC. No language or other restrictions were imposed. Summary estimates of risk factors of LTP were obtained by using a random-effects model with further exploration with meta-regression and sub-group analyses. KEY
FINDINGS: There were 16 studies included, of which 7 were focused on the association of LTP with tumors abutting vessels, and 15 focused on tumors of subcapsular location. In total, 2870 patients were included. Tumors that were located in the subcapsular area had a higher occurrence of LTP (P = 0.04) with a high heterogeneity (I2 = 65%), which could not be explained by the results of the meta-regression. However, tumor that were in close to vessels had contrary results (P = 0.54) with a high heterogeneity (I2 = 77%). SIGNIFICANCE: The findings of the present meta-analysis indicate that the subscapsular location is a possible risk factor of LTP. Nevertheless, a clear definition or classification of the subcapsular location should be highlighted in future studies. Whether tumor location adjacent to a vessel has an influence on the incidence of LTP remains controversial, and more relevant research should be performed.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Local tumor progression; Radiofrequency ablation; Subcapsular; Vessels

Mesh:

Year:  2018        PMID: 29924963     DOI: 10.1016/j.lfs.2018.06.016

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum.

Authors:  Zlatko Devcic; Mohamed Elboraey; Lucas Vidal; Kabir Mody; Denise Harnois; Tushar Patel; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

2.  Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma.

Authors:  Angelo Della Corte; Claudio Sallemi; Francesca Ratti; Lorenzo Monfardini; Simone Gusmini; Federica Cipriani; Renato Pennella; Domenico Santangelo; Valentina Burgio; Andrea Casadei-Gardini; Luca Aldrighetti; Francesco De Cobelli
Journal:  Cardiovasc Intervent Radiol       Date:  2022-09-30       Impact factor: 2.797

3.  Laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for subphrenic hepatocellular carcinoma.

Authors:  Min Hwan Kwak; Min Woo Lee; Seong Eun Ko; Hyunchul Rhim; Tae Wook Kang; Kyoung Doo Song; Jong Man Kim; Gyu-Seong Choi
Journal:  Ultrasonography       Date:  2022-02-09

4.  Laparoscopic Hepatic Resection Versus Laparoscopic Radiofrequency Ablation for Subcapsular Hepatocellular Carcinomas Smaller Than 3 cm: Analysis of Treatment Outcomes Using Propensity Score Matching.

Authors:  Seong Eun Ko; Min Woo Lee; Soohyun Ahn; Hyunchul Rhim; Tae Wook Kang; Kyoung Doo Song; Jong Man Kim; Gyu-Seong Choi; Dong Ik Cha; Ji Hye Min; Dong Hyun Sinn; Moon Seok Choi; Hyo Keun Lim
Journal:  Korean J Radiol       Date:  2022-03-08       Impact factor: 7.109

5.  Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study.

Authors:  Fuqun Wei; Qizhen Huang; Yang Zhou; Liuping Luo; Yongyi Zeng
Journal:  World J Surg Oncol       Date:  2021-06-14       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.